AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

NUFORMIX PLC

Director's Dealing Sep 16, 2021

4941_dirs_2021-09-16_93d8d31a-472c-46cc-ace2-9a938a4446e4.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 0420M

Nuformix PLC

16 September 2021

16 September 2021

Nuformix plc

("Nuformix" or the "the Company")

Director/PDMR Shareholding

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that today the Company received notice that Dr Alastair Riddell, Chairman of the Company, purchased 350,000 ordinary shares of 0.1 pence each ("Ordinary Shares") at a price of 0.0135 pence per share on 16 September 2021.

- Ends -

Enquiries:

Nuformix plc +44 (0) 1223 627 222
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate Finance)
Stefano Aquilino / Matt Butlin (Sales & Corporate Broking)
Walbrook PR

Anna Dunphy / Paul McManus
+44 (0) 20 7933 8780

[email protected]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dr Alastair Riddell

2

Reason for the notification

a)

Position/status

PDMR - Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Nuformix plc

b)

LEI

2138003XG3H3I2J3BJ24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of nominal value 0.1 pence each

GB00BYW79Y38

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
0.0135p 350,000

d)

Aggregated information

- Aggregated volume

- Price

- Total

350,000

0.0135p

£4,725.00

e)

Date of the transaction

16 September 2021

f)

Place of the transaction

London Stock Exchange, Main Market

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPUACBUPGGGQ

Talk to a Data Expert

Have a question? We'll get back to you promptly.